Since all aspects of RTD type 2 disease stem from the loss of SLC52A2 gene function, gene replacement therapy represents a reasonable and promising approach to provide a meaningful benefit for RTD patients. This evidence concerns the gene SLC52A2 and renal tubular dysgenesis of genetic origin.